LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
Not yet recruiting · NCT06472479 · Registry updated 2024-06-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not applicable | 2024-06-28 | NCT06472479 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing Legend Biotech Co. | 13 |
| The First Affiliated Hospital with Nanjing Medical University | 319 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Anhui Cancer Hospital | Hefei | China | 8 |
| Beijing GoBroad Hospital | Beijing | China | 4 |
| Henan Cancer Hospital | Zhengzhou | China | 57 |
| Jiangsu Province Hospital | Nanjing | China | 89 |